. 2010 May-Jun;2(3):256–265. doi: 10.4161/mabs.2.3.11641

Table 1.

Immune responses to fully human antibodies

	Target	Indication	Percent positive	Category (from ref. 5)	Reference
panitumumab	EGFR	Colorectal carcinoma	3–4% 1–4.6% binding ∼1% neutralizing	tolerable	Label (http://www.vectibix.com/pdfs/misc/vectibix_pi.pdf); refs. ⁷⁸, ⁸⁰, ⁸¹
ofatumumab	CD20	Chronic lymphocytic leukemia	0%	negligible	Label (http://us.gsk.com/products/assets/us_arzerra.pdf)
golimumab	TNFalpha	Rheumatoid arthritis Ankylosing spondylitis	2–16% 3–4%	marked tolerable	Label (http://www.simponi.com/simponi///assets/pdf/prescribing-lnformation.pdf); ref. 78
canakinumab	IL-1beta	CAPS	0%	negligible	Label (http://www. pharma.us.novartis.com/product/pi/pdf/ilaris.pdf)
adalimumab	TNFalpha	Rheumatoid arthritis	5–12% 20–89%	tolerable marked	Label (http://www. rxabbott.com/pdf/humira.pdf); refs. ⁷⁴–⁷⁶